Normal view MARC view ISBD view

Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.

Psaty, Bruce M

Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. [electronic resource] - JAMA Mar 2008 - 1474-6 p. digital

Publication Type: Journal Article

ISSN: 1538-3598

Standard No.: 10.1001/jama.299.12.1474 doi

Subjects--Topical Terms:
Azetidines--therapeutic use
Biomarkers
Clinical Trials as Topic
Drug Approval
Ezetimibe
Humans
Hypolipidemic Agents--therapeutic use
Quinolines--therapeutic use
Risk
United States
United States Food and Drug Administration

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)